摘要
目的研究阿托伐他汀联合依那普利治疗老年H型高血压急性脑梗死的疗效及对认知功能障碍、同型半胱氨酸(Hcy)、尿酸(UA)水平的影响。方法选取茂名市人民医院2018年5月-2020年6月期间收治的94例老年H型高血压急性脑梗死认知功能障碍患者为研究对象,根据其用药种类的不同,分为对照组(阿托伐他汀)47例和研究组(阿托伐他汀联合依那普利)47例,观察比较2组患者服药3个月后的血压水平、神经及认知功能评分、治疗效果、Hcy、UA水平及不良反应情况。结果治疗后,研究组患者的舒张压与收缩压均低于对照组(P<0.05);研究组患者的NIHSS评分低于对照组,MMSE评分高于对照组(P<0.05);研究组Hcy、UA水平较对照组低(P<0.05);研究组患者治疗总有效率更高(P<0.05),2组不良反应情况无明显差异(P>0.05)。结论阿托伐他汀联合依那普利治疗老年H型高血压急性脑梗死认知功能障碍患者具有较好的临床效果,患者的血压控制较好,同时认知水平也有显著提升,且未发现明显的不良反应,值得推广。
Objective To study atorvastatin combined with Nega Purli’s effect on the treatment of acute cerebral infarction of elderly H-type high blood pressure and Hcy,UA level. Methods Selected 94 patients with H-type Hypertension acute cerebral infarction cognitive dysfunction in our hospital from May 2018 to June 2020,which was divided into control group47 patients(using Atorvastatin treatment)and the study group 47 patients(using anorvastatin combined with Negari Purli treatment)according to the variety of medication.The blood pressure level,cognitive function score,treatment effect,Hcy,UA levels and adverse reactions were observed after three treatment. Results After treatment,the diastolic pressure and shrinkage pressure in the study group were lower than those of the control group(P <0.05);the NIHSS score in the study group was lower than the control group,and the MMSE score was higher than the control group( P <0.05);At the same time,Hcy and UA levels were lower than those of the control group(P <0.05);the total effectiveness of the study group patients was higher,and there was no significant difference in adverse reactions after continuous treatment in two groups. Conclusion Atorvastatin combine with Negarpril to treat elderly H-type high blood pressure have a good clinical effect. The patient’s blood pressure control is better,and there is also a significant improvement in cognitive level. There is no obvious adverse reaction,it is worthwhile to promote.
作者
代西艳
梁波
吴汉妹
Dai Xiyan;Liang Bo;Wu Hanmei(The People's Hospital of Maoming City,Maoming,Guangdong 525000)
出处
《基层医学论坛》
2022年第19期5-7,共3页
The Medical Forum
基金
茂名市科技计划项目(2020003)。
